David S. Baldwin, Shauna Rudge
Abstract
The search for the ideal antidepressant continues. Moclobemide, the first reversible inhibitor of monoamine oxidase type A to enter widespread clinical use, has a number of advantages over traditional monoamine oxidase inhibitors and represents a valuable addition to the antidepressant armamentarium.
OpenAlex reports 4 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
The search for the ideal antidepressant continues. Moclobemide, the first reversible inhibitor of monoamine oxidase type A to enter widespread clinical use, has a number of advantages over traditional monoamine oxidase inhibitors and represents a valuable addition to the antidepressant armamentarium.
Key concepts: Moclobemide, Monoamine oxidase inhibitor, Medicine, Antidepressant, Monoamine oxidase, Monoamine oxidase A, Pharmacology, Monoamine oxidase B